AbbVie says 8 weeks of treatment with P/G achieved high SVR 12 rates
AbbVie announced high SVR12 rates were achieved with 8 weeks of treatment with its investigational, once-daily, ribavirin-free, pan-genotypic regimen of glecaprevir/pibrentasvir, or G/P, in patients with challenging to treat genotype 3, or GT3, chronic hepatitis C virus, or HCV, infection. In results from the Phase 3 ENDURANCE-3 study, 95% of GT3 chronic HCV infected patients without cirrhosis and who are new to treatment achieved sustained virologic response at 12 weeks post-treatment, or SVR12, following 8 weeks of treatment with G/P. These new data will be featured as an oral presentation today at The International Liver Congress 2017 in Amsterdam, The Netherlands. As well as evaluating 8 weeks of treatment with G/P, the ENDURANCE-3 study was designed to evaluate whether 12 weeks of G/P is non-inferior to 12 weeks of sofosbuvir plus daclatasvir, or SOF+DCV, a current standard of care for GT3 chronic HCV infected patients. SVR12 rates of 95% were seen in both 8 weeks and 12 weeks of treatment with G/P.1 Additionally, 12 weeks of treatment with G/P was demonstrated to be non-inferior to 12 weeks of treatment with SOF+DCV.